This CPB has been revised to state that (i) the use of Lupron for a leuprolide stimulation test for diagnosing hypogonadism and central precocious puberty is considered medically necessary, and (ii) the use of Lupron for the treatment of hypermenorrhea and sickle cell anemia-associated priapism is considered experimental and investigational.  This CPB has also been revised to delete cyproterone acetate from the list of prerequisites for the use of Lupron for paraphilias (in the Appendix).